Brief: Tenax Therapeutics Says Expects Phase 3 Trial Of PAH To Begin In Q2 Of 2022
16/11/2021 13:59
Nov 16 (Reuters) - Tenax Therapeutics Inc TENX.O :
* TENAX THERAPEUTICS INC SAYS GIORDANO WAS PREVIOUSLY
APPOINTED
PRESIDENT, CHIEF EXECUTIVE OFFICER OF THE COMPANY
* TENAX THERAPEUTICS INC - EXPECTS PHASE 3 TRIAL OF
PULMONARY
ARTERIAL HYPERTENSION TO BEGIN IN Q2 OF 2022
Further company coverage: TENX.O
((Reuters.Briefs@thomsonreuters.com;))